Notizia: The Latest Pharma, Healthcare and Biotech Event Archives
Fight Against the Antibiotic Resistance in the Uncomplicated Urinary Tract Infections Market
recent-pharma-news-updates-for-adarx-ixaka-novocure-vor-biopharma
ADARx Raises $75M Series B; Fast Trac...

ADARx bags USD 75 Million to advance its RNA tech pipeline ADARx Pharmaceuticals, a biotechnology company d...

pharma-news-updates-for-roche-mayo-clinic-owlstone-transmedics-google
Roche inks $3B deal; Owlstone raises ...

Roche’s Genentech taps Adaptimmune for T-Cell Therapy Collaboration for USD 3 Billion A collaboration value...

recent-pharma-news-and-updates-for-Pfizer-Forte-Biosciences- Bone-Therapeutics-Versanis-Bio-AC-Immune
Pfizer’s RSV Vaccine; Forte Bioscienc...

Pfizer’s RSV Vaccine enters in the late-stage of clinical trials  As the battle to get an effective Re...

medtech-news-and-updates-for-abiomed-helius-smart-meter-bd-veritor-xact
Abiomed’s Impella ECP; Helius’s PoNS Device; Smart Meter’s iGlucose BGM; XACT’s CT-Guided Percuta...

FDA awards Breakthrough Device Designation to Impella ECP On August 18, 2021, Abiomed received breakthrough device designation from the United States Food and Drug Administration (FDA) fo...


pharma-news-and-updates-for-Ascendis-MicroTransponder-BioMarin-Zimmer-Biomet-Canary-Medical
Ascendis’s SKYTROFA; MicroTransponder’s VNS System (Vivistim); BioMarin’s Voxzogo; Zi...

FDA's Green Flag to Ascendis's Once-Weekly SKYTROFA for Treatment of Pediatric Growth Hormone DeficiencyFor the treatment of growth failure due to deficiency of growth hormones, the USFDA appr...


pharma-happenings-for-roche-allstripes-datavant-bluewillow-shape-therapeutics
Shape Therapeutics-Roche’s Deal; AllStripes Raises $50M; Datavant-Real Chemistry’s Pa...

Shape Therapeutics inks gene therapy deal with Roche worth up to USD 3 BillionSeattle biotech firm Shape Therapeutics has signed a deal potentially exceeding USD 3 billion with pharma giant Ro...


recent-pharma-news-updates-for-hebabiz-pfizer-astrazeneca-bms-masimo
AstraZeneca’s Ultomiris; HebaBiz’s Siroquine; Pfizer’s XELJANZ; Bristol Myers S...

AstraZeneca's Newly Occupied Alexion Hits Rock Bottom After Ultomiris (Ravulizumab) Fails to Show Efficacy in Patients with Amyotrophic Lateral SclerosisAstraZeneca's 39 billion USD complete a...


medtech-news-updates-for-boston-scientific-kestra-zoll-fujifilm-cytosorbents-lunit
Boston Scientific’s EkoSonic; FDA clearance for EXALT; Kestra Medical’s ASSURE; ZOLL Next-Generat...

Boston Scientific starts recruitment for randomized controlled trials for the EkoSonic™ Endovascular SystemOn August 04, 2021, Boston Scientific Corporation started the enrolment in the...


pharma-news-updates-for-merck-eisai-fibrogen-jazz-pfizer-ipsen-seagen
FDA approval to Keytruda and Lenvima; FibroGen’s Roxadustat; Pfizer’s TICOVAC; Ipsen’s Palo...

FDA’s Green Flag to Keytruda and Lenvima combination by Merck and Eisai for Advanced renal cell carcinoma (RCC)The FDA approved the combination of Keytruda and Lenvima produced by Merck and Ei...


Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmo...

According to WHO, Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death g.....

Myelodysplastic Syndrome (MDS) Market Analysis
Myelodysplastic Syndrome ...

Well, MDS being one of the rare blood cancers, has been into the limelight of researchers since a de.....

Prostate Cancer
Prostate Cancer...

Prostate Cancer is the second most common malignancy in men worldwide, after lung cancer. Most Prost.....

Editor's Pick
Intratumoral Cancer Therapy: A Potential Weapon To Fight the Battle Against C...

Cancer is a leading cause of global death, accounting for nearly 10 million deaths in 2...

Angelman syndrome Pipeline: Unmet needs call for a robust pipeline

The necessity of a robust Angelman syndrome pipeline is indispensable at the current mo...

The New Buzz of Transcranial Stimulation Devices in the Neurological Disorder...

Neurological disorders are one of the major causes of death and disability across the g...

Leading Autoimmune Diseases to Undergo Robust Improvement in Treatment by Maj...

As per the American Autoimmune Related Diseases Association (AARDA), nearly 50 million ...

Unity’s advanced vascular eye disease trial; Rallybio raises $100 M; Sa...

UNITY Biotechnology declares positive data from phase 1 clinical trial of UBX1325 in Ad...